Abstract 1234P
Background
Recently, the field of digital pathology has seen an increase in research utilizing deep learning techniques. This allows for predictions such as cancer diagnosis, prognosis, and treatment response, which previously required additional analysis, such as genetic analysis that was both time-consuming and costly, to be made based on pathological imaging. However, digital pathology images often contain noise, such as inconsistent staining and inconsistent annotations. To address this issue, image preprocessing is essential in deep learning analysis of digital pathology images, and various preprocessing techniques have been proposed to address issues such as bias, overfitting, and robust deep learning model development. However, automated preprocessing methods for digital pathology images have not yet been fully developed.
Methods
To address this, we have developed a user-friendly tool for image preprocessing analysis called HistoMate.
Results
HistoMate provides GUI-based image segmentation, image tiling, color normalization, and deep learning-based data augmentation to automate the preprocessing process. It also provides functionality to evaluate image quality and select appropriate patches.
Conclusions
In conclusion, HistoMate provides an automated preprocessing tool for pathological image-based research, accelerating digital pathology-based research.
Clinical trial identification
Editorial acknowledgement
This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korean Government (MSIT) (grant no. NRF-2021R1C1C1013706), and research fund by Seoul National University Bundang Hospital (grant no. 14-2018-0013).
Legal entity responsible for the study
The authors.
Funding
This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korean Government (MSIT) (grant no. NRF-2021R1C1C1013706), and research fund by Seoul National University Bundang Hospital (grant no. 14-2018-0013).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1807P - Talazoparib (TALA) plus enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC): Subgroup analyses of the all-comers cohort from TALAPRO-2 by homologous recombination repair (HRR) status
Presenter: Nobuaki Matsubara
Session: Poster session 14
1808P - Pain response and health-related quality of life (HRQL) analysis in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel every 2 weeks (16 mg/m<sup>2</sup>) versus every 3 weeks (25 mg/m<sup>2</sup>) in the CABASTY phase III trial
Presenter: Stephane Oudard
Session: Poster session 14
1809P - Dynamics of plasma tumour DNA and copy number alterations in advanced metastatic castration-resistant prostate cancer (mCRPC) patients treated with cabazitaxel: A prospective biomarker trial
Presenter: Nicole Brighi
Session: Poster session 14
1810P - Association of health-related quality of life with efficacy outcomes in the VISION study of patients with metastatic castration-resistant prostate cancer
Presenter: Michael Morris
Session: Poster session 14
1811P - Patient-reported outcomes (PROs) in men with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) mutations receiving talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA: Results from a phase III (TALAPRO-2) study
Presenter: Andre Fay
Session: Poster session 14
1813P - Phase I/II trial of oral EPI-7386 in combination with enzalutamide (enz) compared to enz alone in metastatic castration-resistant prostate cancer (mCRPC) subjects: Current phase I (PI) results
Presenter: Andrew Laccetti
Session: Poster session 14
1814P - First real-life data on [177Lu]Lu-PSMA-617: Descriptive analysis on the largest metastatic castration-resistant prostate cancer (mCRPC) cohort treated in early access in France
Presenter: Anne-Laure Giraudet
Session: Poster session 14
1815P - Emergent circulating tumor DNA (ctDNA) variants and ctDNA burden dynamics with potential associations with talazoparib antitumor activity in TALAPRO-1
Presenter: Elena Castro
Session: Poster session 14